Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression

被引:0
|
作者
Mueller, MM [1 ]
Fusenig, NE [1 ]
机构
[1] German Canc Res Ctr, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany
关键词
D O I
10.1002/(SICI)1097-0215(19991210)83:6<780::AID-IJC14>3.3.CO;2-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor progression is characterized by an increasing escape of tumor cells from the growth control of their microenvironment, often caused by aberrant expression of growth factors. In the human skin carcinoma model system, based on the HaCaT keratinocyte line, tumor progression to high-grade malignant cells is associated with constitutive expression and secretion of the hematopoietic growth factors G-CSF and GM-CSF in vitro and in vivo. All HaCaT keratinocyte variants express the G-CSF and the GM-CSF receptors at levels comparable to normal keratinocytes. Consequently, they exhibit: a stimulation of cell proliferation and migration in culture when treated with these factors. Moreover, both proliferation and migration of the high-grade malignant cells were strongly inhibited by neutralizing antibodies to G-CSF and GM-CSF, respectively. This demonstrates the functional role of these factors in high-grade malignant HaCaT cells through an autocrine mechanism in vitro and implies their significance in tumor progression in vivo. In light: of the increasing use of G-CSF and GM-CSF in adjuvant tumor therapy, our data, as well as those discussed for head-and-neck tumors and gliomas, warrant a careful re-evaluation of the clinical application of both factors. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:780 / 789
页数:10
相关论文
共 50 条
  • [41] Rational therapy with hematopoietic growth factors G-CSF and GM-CSF [Rationale therapie mit den hämatopoetischen wachstumsfaktore, G-CSF und GM-CSF]
    Link H.
    Hess C.F.
    Albers P.
    Schmoll H.J.
    Reimers H.J.
    Von Minckwitz G.
    Nowrousian M.R.
    Welte K.
    Der Onkologe, 2001, 7 (12): : 1329 - 1341
  • [42] Functional deficiencies of peritoneal cells from gene-targeted mice lacking G-CSF or GM-CSF
    Zhan, YF
    Basu, S
    Lieschke, GJ
    Grail, D
    Dunn, AR
    Cheers, C
    JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (02) : 256 - 264
  • [43] SYNERGISTIC EFFECTS BETWEEN GM-CSF AND G-CSF OR M-CSF ON HIGHLY ENRICHED HUMAN MARROW PROGENITOR CELLS
    BOT, FJ
    VANEIJK, L
    SCHIPPER, P
    BACKX, B
    LOWENBERG, B
    LEUKEMIA, 1990, 4 (05) : 325 - 328
  • [44] Treatment of agranulocytosis with colony stimulating factor (G-CSF or GM-CSF)
    Krykowski, E
    GoraTybor, J
    Fronczak, A
    Robak, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1037 - 1037
  • [45] DIFFERENTIAL EFFECT OF G-CSF AND GM-CSF IN ACQUIRED CHRONIC NEUTROPENIA
    WODZINSKI, MA
    HAMPTON, KK
    REILLY, JT
    BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (02) : 249 - 250
  • [46] G-CSF and GM-CSF after BMT in children with AML.
    Gedikooglu, G
    Anak, S
    Yalman, N
    Babaliogliu, M
    Bilgen, H
    Ozgenc, S
    Can, E
    BONE MARROW TRANSPLANTATION, 1998, 21 : S104 - S104
  • [47] COMPARISON OF TOXICITIES OF G-CSF AND YEAST-DERIVED GM-CSF
    BEVERIDGE, RA
    KALES, AN
    BINDER, RA
    ROBERT, NJ
    MILLER, JA
    BLOOD, 1993, 82 (10) : A495 - A495
  • [48] THE USE OF G-CSF AND GM-CSF IN BONE-MARROW TRANSPLANTATION
    BOLWELL, BJ
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1993, 60 (04) : 291 - 302
  • [49] Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia
    Wang, S
    Degar, BA
    Zieske, A
    Shafi, NQ
    Rose, MG
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (04) : 391 - 396
  • [50] GM-CSF and G-CSF - potential therapeutic targets in inflammatory diseases
    Wicks, I.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 : 15 - 15